Keralink International, Inc. v. Stradis Healthcare, LLC

District Court, D. Maryland·Decided May 14, 2020·No. 1:18-cv-02013·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND

KERALINK INTERATIONAL, INC., * * v. * Civil No. CCB-18-2013 * STRADIS HEALTHCARE, LLC, et al. * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

MEMORANDUM Keralink International, Inc. (“Keralink”) filed suit against Stradis Healthcare, LLC (“Stradis”) and Geri-Care Pharmaceuticals Corporation (“Geri-Care”), alleging tort and contract claims. (ECF 75).1 Stradis filed a third-party complaint against Insource, Inc. (“Insource”) and Geri-Care for contribution, (ECF 10),2 and Insource filed a crossclaim against Geri-Care, (ECF 45). Now pending is Geri-Care’s motion to dismiss Insource’s crossclaim, (ECF 49), and Insource’s cross motion to strike Geri-Care’s motion to dismiss, (ECF 51). The motions are fully briefed and no hearing is necessary. For the reasons explained below, the court will grant Geri- Care’s motion, deny Insource’s motion, and dismiss the crossclaim without prejudice. BACKGROUND3 Keralink, a national network of eye banks, is headquartered in Maryland. (Second Amended Complaint (“SAC”) ¶ 6, ECF 75). Keralink recovers and distributes ocular tissue for use in corneal transplants, (id.), and purchases the medical supplies it needs to preserve and distribute ocular tissue from various vendors, (id. ¶ 10). Stradis, one of Keralink’s vendors,

1 Keralink’s original complaint brought claims only against Stradis, (see ECF 1), but Keralink has since added Geri- Care as a defendant, (see ECF 58 (first amended complaint); ECF 75 (second amended complaint)). 2 Stradis also named as a third-party defendant Kareway Product, Inc. (“Kareway”). (ECF 10). The court, however, dismissed the third-party complaint as to Kareway for lack of personal jurisdiction, (ECF 35, 36), and Kareway is no longer a party to this case. 3 The procedural history of this case is complex, and the court recites the minimum facts necessary. provided Keralink with surgical packs. (Id.). These packs contained supplies that Keralink used to recover corneal tissue from deceased donors. (Id. ¶ 13). This litigation arises from the inclusion of contaminated sterile eye wash (“Geri-Care Eye Wash”) in sterile surgical packs Keralink purchased from Stradis. (SAC ¶¶ 16–17). In October 2017, the Eye Bank Association of America notified its members that batches of Geri-Care Eye

Wash may be contaminated by bacteria. (Id. ¶ 22). As federal regulations prohibit the use of contaminated ocular tissue, Keralink quarantined ocular tissue that had been recovered using Geri-Care Eye Wash. (Id. ¶¶ 23–24). All told, Keralink could not use 61 live-cell tissues and 860 long-term tissues that had been exposed to Geri-Care Eye Wash. (Id. ¶ 24). Keralink alleges that it has sustained no less than $600,000 in total damages. (Id. ¶ 28). Stradis subsequently filed a third-party complaint against Insource and Geri-Care,4 seeking indemnification and contribution. (ECF 10). Stradis alleges that Insource “designed, tested, packaged, labeled, manufactured, distributed, supplied and/or produced the GeriCare Eye Wash identified in the Complaint.” (Id. ¶ 28). Insource filed a crossclaim against Geri-Care,

alleging one count of “Breach of Contract and Indemnification Against Geri-Care.” (ECF 45). The crossclaim alleges that Insource is a subsidiary of Henry Schein, Inc., and that pursuant to a Continuing Guaranty and Indemnification Agreement, Geri-Care agreed to indemnify and hold harmless Henry Schein Inc. or any affiliates or subsidiary thereof against any and all costs, claims, damages, and liabilities as a result of any alleged or actual use or misuse of the Geri-Care products shipped and/or delivered to Henry Schein or as a result of any breach by Geri-Care in connection with the manufacture, development, sale, distribution, storage or dispensing of its products including but not limited to litigation fees and expenses, reasonable attorneys’ fees and expenses.

(ECF 45 at 2).

4 Stradis also named Kareway as a third-party defendant, but the court dismissed the claim for lack of personal jurisdiction. See supra note 2. Geri-Care moves to dismiss the crossclaim on the grounds that: (1) Insource does not plead the court’s basis for subject matter jurisdiction; (2) the court should not exercise supplemental jurisdiction over the claim; (3) Insource has failed to state a claim on which relief can be granted; and (4) the crossclaim does not comply with Federal Rule of Civil Procedure 13(g). In response, Insource filed a motion to strike Geri-Care’s motion. (ECF 51). In addition to

disputing each of Geri-Care’s arguments for dismissal of the cross claim, Insource argues that Geri-Care’s motion to dismiss should be stricken as untimely. ANALYSIS I. Timeliness of Geri-Care’s motion As an initial matter, the court considers Insource’s argument that Geri-Care’s motion to dismiss should be stricken as untimely. Insource filed its crossclaim on August 16, 2019, and Federal Rule of Civil Procedure 12(a)(1)(B) states that “[a] party must serve an answer to a counterclaim or crossclaim within 21 days after being served with the pleading that states the counterclaim or crossclaim.” Geri-Care was thus required to respond by September 6, 2019, but

did not file its motion to dismiss until September 9, 2019. Geri-Care asserts that its failure to timely file its motion was due to excusable neglect, and asks the court to grant an after-the-fact extension pursuant to Federal Rule of Civil Procedure 6(b)(1)(B) (“the court may, for good cause, extend the time . . . after the time has expired if the party failed to act because of excusable neglect”). (See ECF 54 at 3–4). The court considers four factors in determining whether a party acted with “excusable neglect”: (1) the danger of prejudice to the opposing party; (2) the length of the delay and its potential impact on judicial proceedings; (3) the reason for the delay; and (4) whether the movant acted in good faith. See In re MI Windows & Doors, Inc., Prod. Liab. Litig., 860 F.3d 218, 226 (4th Cir. 2017) (citing Pioneer Inv. Servs. Co. v. Brunswick Assocs. Ltd. P’ship, 507 U.S. 380, 395 (1993)). On balance, the court finds that Geri-Care’s late filing was due to excusable neglect. Insource has not alleged that the late filing prejudiced it in any way; the delay was fairly short (three calendar days, or one business day); Geri-Care asserts that the delay was due to counsel’s

mistaken calculation of the due date; and there is no indication of bad faith. Accordingly, the court declines to strike Geri-Care’s motion as untimely. II. Geri-Care’s arguments for dismissal Geri-Care’s motion sets out four reasons that the court should dismiss Insource’s crossclaim. As explained below, while one issue alone might not be enough to warrant dismissal of the crossclaim, the combination of several issues leads the court to conclude that dismissal without prejudice is the appropriate course of action here. A. Pleading deficiencies Two of Geri-Care’s arguments for dismissal relate to Insource’s failure to adhere to

pleading requirements: (1) failure to plead subject matter jurisdiction and (2) failure to comply with Rule 13(g). First, Federal Rule of Civil Procedure

Free access — add to your briefcase to read the full text and ask questions with AI

Keralink International, Inc. v. Stradis Healthcare, LLC, (D. Md. 2020).

Keralink International, Inc. v. Stradis Healthcare, LLC (Keralink International, Inc. v. Stradis Healthcare, LLC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Wag More Dogs, Ltd. Liability Corp. v. Cozart
680 F.3d 359 (Fourth Circuit, 2012)
Bizzie Walters v. Todd McMahen
684 F.3d 435 (Fourth Circuit, 2012)
RaceRedi Motorsports, LLC v. Dart MacHinery, Ltd.
640 F. Supp. 2d 660 (D. Maryland, 2009)
Commercial Union Insurance v. Porter Hayden Co.
698 A.2d 1167 (Court of Special Appeals of Maryland, 1997)
Pinkley Inc v. City of Frederick MD
191 F.3d 394 (Fourth Circuit, 1999)